News

Ingrezza treatment eases disease burden due to Huntington’s chorea

Daily treatment with Ingrezza (valbenazine) led to reductions in motor- and cognitive-related disease burden for adults with chorea due to Huntington’s disease, according to new data analyses from the Phase 3 KINECT-HD clinical trial. These changes were assessed with a relatively new patient-reported measure, called the Huntington’s Disease…

HDSA 2025: Dance classes may improve balance in Huntington’s

Participating in dance classes may help people with Huntington’s disease improve their balance and maintain their functional capacity, according to the results of a small U.S. pilot study in which patient mobility was assessed before and after an intervention program. The researchers shared the results in a talk titled…

HDSA 2025: Long-term care transition requires communication

Long-term care facilities can help people with Huntington’s disease thrive, and successfully managing the transition into long-term care requires cooperation and communication from everyone involved, social workers said. Caregivers need to pay attention to “indicators,” assessments of what a person can do without assistance — that can involve anything…

HDSA 2025: Speakers spotlight Huntington’s clinical trials

Several treatments aiming to reduce levels of mutant huntingtin (mHTT), the protein that drives Huntington’s disease, are being tested in clinical trials or may soon enter clinical testing. Company representatives described those therapies in a luncheon session at the 40th annual Huntington’s Disease Society of America (HDSA) convention,…

HDSA 2025: Early planning key for navigating care over time

Taking steps to plan ahead, including having difficult discussions early on, can help people with Huntington’s disease and their families navigate life as the disease progresses and care needs evolve. That’s according to speakers at the Huntington’s Disease Society of America (HDSA) annual convention, held June 26-28 in…